Abstract
e11557 Background: Docetaxel (Dc) is a major drug in metastatic breast cancer (MBC). At progression, rechallenge with docetaxel can be discussed based on the previous efficacy and tolerance. No data on this pragmatic strategy are avalaible in MBC. Methods: We identify 73 patients (pts) with the following criteria: (i) objective response or stable disease with a previous line of treatment with Dc in MBC, (ii) rechallenge with Dc (on a three weekly schedule) for progressive disease after a minimal Dc-free interval of 3 months. The main objectives were to evaluate the overall response, the time to progression (TTP) and toxicity at reintroduction of TXT. Results: Median age was 57 years (34 - 84). Patients had already received 1, 2, 3, ≥ 4 lines of chemotherapy (including the first use of Dc) in 20%, 47%, 18% and 15% of cases, including capecitabine, anthracycline, and vinorelbine in 56%, 40% and 21% of cases, respectively. Visceral disease was described in 80% of cases. The median number of cycles was 6 (1-18). Overall, 57 pts (78%) obtained a symptomatic benefit from the treatment. Among the 32 pts (44%) with disease assessed according to RECIST criteria, 14 (44%) had a partial response and 11 (34%) had a stable disease > 3 months. Among the 41 pts without an available evaluation according to RECIST, 22 (54%) experienced a biological partial response. The median TTP was 5.9 months (95%CI [4.9-6.9]). The median overall survival (OS) was 10.8 months (95%CI [9.1-12.5]). Toxicity was manageable. Forty seven pts (64%) reported grade 1/2 toxicity, mostly mucositis (37%), asthenia (34%) and nails toxicity (30%). Twenty six pts (36%) experienced grade 3/4 toxicity, mostly neutropenia (16%) and fluid retention (11%). Predictive factors of benefit at re-introduction of TXT are in progress. Conclusions: This retrospective analysis supports the pragmatic strategy to retreat patients with MBC with Dc provided that this drug had shown previous activity and was stopped for other causes than progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
